Dr. Sunnie Kim, MD
Claim this profileUniversity of Colorado
Studies Solid Tumors
Studies Stomach Cancer
6 reported clinical trials
11 drugs studied
Area of expertise
1Solid Tumors
Stage IV
metastatic
relapsed
2Stomach Cancer
Stage IV
HER2 positive
FANCE positive
Affiliated Hospitals
Clinical Trials Sunnie Kim, MD is currently running
Pembrolizumab + Olaparib
for Pancreatic Cancer
This phase II trial studies whether adding pembrolizumab to olaparib (standard of care) works better than olaparib alone in treating patients with pancreatic cancer with germline BRCA1 or BRCA2 mutations that has spread to other places in the body (metastatic). BRCA1 and BRCA2 are human genes that produce tumor suppressor proteins. These proteins help repair damaged deoxyribonucleic acid (DNA) and, therefore, play a role in ensuring the stability of each cell's genetic material. When either of these genes is mutated, or altered, such that its protein product is not made or does not function correctly, DNA damage may not be repaired properly. As a result, cells are more likely to develop additional genetic alterations that can lead to some types of cancer, including pancreatic cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Olaparib is an inhibitor of PARP, a protein that helps repair damaged DNA. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. The addition of pembrolizumab to the usual treatment of olaparib may help to shrink tumors in patients with metastatic pancreatic cancer with BRCA1 or BRCA2 mutations.
Recruiting1 award Phase 237 criteria
SBRT + Olaparib and Pembrolizumab + Olaparib
for Gastric Cancer
This trial tests a treatment for patients with advanced stomach and GEJ cancers who have not responded to previous treatments. It uses a drug called olaparib, precise radiation therapy, and a combination of olaparib and pembrolizumab to damage cancer cells' DNA, target them accurately, and help the immune system fight the cancer.
Recruiting1 award Phase 25 criteria
More about Sunnie Kim, MD
Clinical Trial Related2 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Sunnie Kim, MD has experience with
- Pembrolizumab
- Olaparib
- Tucatinib
- Trastuzumab
- Fluorouracil
- Capecitabine
Breakdown of trials Sunnie Kim, MD has run
Solid Tumors
Stomach Cancer
Adenocarcinoma
Colorectal Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Sunnie Kim, MD specialize in?
Sunnie Kim, MD focuses on Solid Tumors and Stomach Cancer. In particular, much of their work with Solid Tumors has involved Stage IV patients, or patients who are metastatic.
Is Sunnie Kim, MD currently recruiting for clinical trials?
Yes, Sunnie Kim, MD is currently recruiting for 2 clinical trials in Aurora Colorado. If you're interested in participating, you should apply.
Are there any treatments that Sunnie Kim, MD has studied deeply?
Yes, Sunnie Kim, MD has studied treatments such as Pembrolizumab, Olaparib, Tucatinib.
What is the best way to schedule an appointment with Sunnie Kim, MD?
Apply for one of the trials that Sunnie Kim, MD is conducting.
What is the office address of Sunnie Kim, MD?
The office of Sunnie Kim, MD is located at: University of Colorado, Aurora, Colorado 80045-2517 United States. This is the address for their practice at the University of Colorado.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.